- Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers
-
Liang LY, Wong VWS, Wong GLH, Yip TCF
- KMID: 2538207
- Clin Mol Hepatol.
- 2023 Jan;29(1):113-117.
- doi: 10.3350/cmh.2022.0333
-
- CITED
-
- Close
- SHARE
-
- Close
- Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact
-
Yip TCF, Wong GLH, Wong VWS
- KMID: 2514767
- Clin Mol Hepatol.
- 2021 Apr;27(2):273-277.
- doi: 10.3350/cmh.2021.0019
-
- CITED
-
- Close
- SHARE
-
- Close
- Dipeptidyl peptidase-4 inhibitors are associated with improved survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy: Letter to the editor on “Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?”
-
Yiu DCY, Lin H, Wong VWS, Wong GLH, Liu K, Yip TCF
- KMID: 2560099
- Clin Mol Hepatol.
- 2024 Oct;30(4):970-973.
- doi: 10.3350/cmh.2024.0280
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
-
Yew KC, Wong SH, Wong VWS, Oon HH
- KMID: 2549390
- Clin Mol Hepatol.
- 2024 Jan;30(1):118-120.
- doi: 10.3350/cmh.2023.0472
-
- CITED
-
- Close
- SHARE
-
- Close
- Implications of comorbidities in nonalcoholic fatty liver disease
-
Song SJ, Wong VWS
- KMID: 2541424
- Clin Mol Hepatol.
- 2023 Apr;29(2):384-389.
- doi: 10.3350/cmh.2023.0066
-
- CITED
-
- Close
- SHARE
-
- Close
- The new definition of metabolic dysfunction-associated steatotic liver disease: the role of ultrasound and elastography
-
Jin X, Yip TCF, Wong GLH, Wong VWS, Lai JCT
- KMID: 2567439
- Ultrasonography.
- 2025 May;44(3):189-201.
- doi: 10.14366/usg.24219
In 2023, nonalcoholic fatty liver disease was renamed metabolic dysfunction-associated steatotic liver disease by the American and European liver associations. This new nomenclature recognizes metabolic dysfunction as the central driver... -
- CITED
-
- Close
- SHARE
-
- Close
- Towards unification of liver stiffness measurement cutoffs: Editorial on “Optimal cut-offs of vibrationcontrolled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”
-
Zhang Y, Wong VWS
- KMID: 2563426
- Clin Mol Hepatol.
- 2025 Jan;31(1):264-267.
- doi: 10.3350/cmh.2024.0766
-
- CITED
-
- Close
- SHARE
-
- Close
- What is new in the 2024 Chinese guidelines for fatty liver disease?
-
Yang RX, Wong VWS, Fan JG
- KMID: 2569166
- Clin Mol Hepatol.
- 2025 Jul;31(3):e239-e246.
- doi: 10.3350/cmh.2024.1165
-
- CITED
-
- Close
- SHARE
-
- Close
- Application of transient elastography in nonalcoholicfatty liver disease
-
Zhang X, Wong GLH, Wong VWS
- KMID: 2500376
- Clin Mol Hepatol.
- 2020 Apr;26(2):128-141.
- doi: 10.3350/cmh.2019.0001n
Nonalcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease worldwide. Although it has become one of the leading causes of cirrhosis and hepatocellular carcinoma in the... -
- CITED
-
- Close
- SHARE
-
- Close
- Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
-
Yip TCF, Lyu F, Lin H, Li G, Yuen PC, Wong VWS, Wong GLH
- KMID: 2539799
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S171-S183.
- doi: 10.3350/cmh.2022.0426
Inflammation is the key driver of liver fibrosis progression in non-alcoholic fatty liver disease (NAFLD). Unfortunately, it is often challenging to assess inflammation in NAFLD due to its dynamic nature... -
- CITED
-
- Close
- SHARE
-
- Close
- Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease
-
Wang Y, Song SJ, Jiang Y, Lai JCT, Wong GLH, Wong VWS, Yip TCF
- KMID: 2565371
- Clin Mol Hepatol.
- 2025 Feb;31(Suppl):S51-S75.
- doi: 10.3350/cmh.2024.0246
In managing metabolic dysfunction-associated steatotic liver disease, which affects over 30% of the general population, effective noninvasive biomarkers for assessing disease severity, monitoring disease progression, predicting the development of liver-related... -
- CITED
-
- Close
- SHARE
-
- Close
- Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B
-
Liang LY, Lee HW, Wong VWS, Yip TCF, Tse YK, Hui VWK, Lui GCY, Chan HLY, Wong GLH
- KMID: 2517633
- Clin Mol Hepatol.
- 2021 Jul;27(3):499-509.
- doi: 10.3350/cmh.2020.0333
Background/Aims: Serum fibrosis scores comprised of common laboratory tests have high utility to assess severity of liver fibrosis. We aimed to derive and validate a hepatocellular carcinoma (HCC) risk score... -
- CITED
-
- Close
- SHARE
-
- Close
- U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases
-
Lin H, Wong GLH, Zhang X, Yip TCF, Liu K, Tse YK, Hui VWK, Lai JCT, Chan HLY, Wong VWS
- KMID: 2523873
- Clin Mol Hepatol.
- 2022 Jan;28(1):77-90.
- doi: 10.3350/cmh.2021.0188
Background/Aims: We aimed to determine the association between blood urea level and incident cirrhosis, hepatic decompensation, and hepatocellular carcinoma in chronic liver disease (CLD) patients. Methods: The association between blood urea... -
- CITED
-
- Close
- SHARE
-
- Close
- HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study
-
Wong VWS, Neff GW, Di Bisceglie AM, Bai R, Cheng J, Yu M, Liberman A, Liu L, Gunn N
- KMID: 2569160
- Clin Mol Hepatol.
- 2025 Jul;31(3):1071-1083.
- doi: 10.3350/cmh.2025.0145
Background/Aims: Berberine ursodeoxycholate (HTD1801) has been shown to significantly reduce liver fat content (LFC) in an 18-week, placebo-controlled Phase 2 study in patients with metabolic dysfunction-associated steatohepatitis (MASH) and type... -
- CITED
-
- Close
- SHARE
-
- Close
